Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic HIPEC for High-Risk Gallbladder Adenocarcinoma
NCT05430035Phase 1Recruiting
- Sponsor
- West Virginia University
- Start
- Jun 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mitomycin c in gallbladder adenocarcinoma, sponsored by West Virginia University. Primary endpoints: Occurrences of intraoperative complications, Occurrences of Postoperative Morbidity and Mortality and 2 more. Started Jun 2022; status: recruiting.
02
Drugs
mitomycin c
03
Conditions
gallbladder adenocarcinoma
Beyond the preview
Go deeper on NCT05430035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05430035.